

June 3, 2011

Dear Sirs:

One of our main goals at AstraZeneca is to make a meaningful difference to patient health through medicines that bring benefit for patients. An important component of this goal is the protection of the integrity of our supply and distribution chains in order to make sure that our patients receive reliably authentic products. In order to safeguard our patients' safety and secure the supply of authentic medicines into the market, AstraZeneca recently adopted a "Zero Tolerance Policy". This policy applies to all our business partners in the supply and distribution chains.

The policy aims to assure that business relations are established only with companies that are not involved in illegal activities, more particularly those activities related to counterfeit medicines, illegal diversion of pharmaceutical products and/or handling and distribution of stolen products. In summary, the policy provides that if a business partner, or an employee of a business partner who acted with the knowledge of his/her employer, is convicted of a crime involving counterfeiting or illegal trade, or if there is sufficient evidence that a business partner has been involved in such activity, either as a deliberate act or through failure to establish appropriate controls, we will terminate the business relation on a first offense.

"Zero Tolerance" is a clear, firm and permanent policy. We believe that it represents an opportunity to work together to protect our patients and strengthen the integrity of our supply and distribution chains.

We invite you to review your processes and internal controls in order to identify weaknesses and correct them as soon as possible. We would also be pleased to discuss any questions that you may have in connection with the "Zero Tolerance" policy implementation.

Please be sure to inform your colleagues and employees about the content of this letter in order to make sure that everyone at your business is aware of the scope and implementation of the "Zero Tolerance" policy.

Finally, during 2011 we will be reviewing and updating as appropriate all of our agreements with your company in order to assure that they align with AstraZeneca policies, including our Zero Tolerance Policy.

Thank you in advance for your attention and cooperation.

Sincerely yours,



Michael Crawford
VP, Supply Chain & Business Planning – Americas Region
AstraZeneca Pharmaceuticals
Michael.Crawford@astrazeneca.com